Best Agrolife Limited — Q4 FY26
Best Agrolife reported a weak FY26 with consolidated revenue of ₹1,257 crore, down 31% YoY, and PAT of just ₹9 crore (vs ₹70 crore in FY25).
bearish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
73%Questions answered1Evaded / deflected11Questions auditedContradictedNumbers vs filing
Partial answer
High priority
Strategic levers for FY26-27 to expand portfolio, distribution, and manage risks.
Asked by Sukrit Dartil, Eyesight Frade Private Limited
Management described initiatives but gave no quantified targets or timelines for portfolio expansion or risk mitigation.
no specific revenue or margin targets givenvague on regulatory risk management
Read the exchange
Question
What type of strategic levers are you prioritizing in FY2627 to expand the company's crop protection portfolio, strengthen distribution network across India and manage risk from regulatory changes and raw material price volatility.
Surendra (CEO)
We have introduced five new bio-stimulant products for FY2627. We will continue introducing new patented products. We are progressing on nano-urea registration. We are pruning non-performing dealers from our 10,800+ network. On risks, we are agile on pricing and monitoring El Nino impact.
Partial answer
High priority
Capital allocation and risk management framework for FY26-27.
Asked by Sukrit Dartil, Eyesight Frade Private Limited
Management gave some qualitative actions but no quantified capital allocation plan or hedging strategy.
no specific capex or R&D budget numbersno forex hedging details
Read the exchange
Question
Forward guidance on capital allocation and risk management framework applied in 27 to balance working capital, R&D funding, forex/raw material hedge, and liquidity buffers for seasonal demand.
Viki (CFO)
We are postponing new capex. R&D spend continues at ~1% of sales. We have filed 100+ patents. We did two rounds of price increases in April and May. We have applied for additional 20% bank funding from government scheme.
Answered
Medium priority
Percentage of sales from own manufacturing vs trading.
Asked by KL, Gojun Capital
Management gave a clear percentage range for own manufacturing sales.
Read the exchange
Question
How much of sales are coming from own manufacturing out of 100%?
Viki (CFO)
Almost between 60 to 65% of our sales are being produced in our own factories.
Partial answer
Medium priority
Capital required to replicate current manufacturing capacity.
Asked by KL, Gojun Capital
Management gave a broad range but noted the technical facility is more complex and not easily replicable.
range given but not precisedistinction between formulation and technical facility not fully quantified
Read the exchange
Question
How much capital would be required to set up whatever manufacturing capabilities we have currently?
Viki (CFO) and Surendra (CEO)
At least 80 to 100 crores to set up a similar manufacturing facility. But technical facility built over 6-7 years with multiple expansions.
Answered
High priority
Margins and working capital cycle for branded vs institutional.
Asked by KL, Gojun Capital
Management provided specific margin percentages and working capital days for both segments.
Read the exchange
Question
What are the margins and working capital cycle for branded compared to institutional?
Viki (CFO)
Branded gross margin ~40%, B2B ~15-20%. Inventory days: branded 120-150, B2B 90-120. Receivables: branded ~120 days, B2B ~90 days. EBITDA margin for branded 18-20%, B2B ~8%.
Answered
High priority
Concern about high receivables and potential write-offs.
Asked by KL, Gojun Capital
Management gave specific historical write-off percentages and explained seasonal collection pattern.
Read the exchange
Question
Receivables worth 500 crores, sales roughly 1,000 crores. Over 200 crores are above 6 months. Possibility of write-offs?
Viki (CFO)
Last three years doubtful debts less than 1%. We have legal cases on only ~22 crores over three years. Most receivables >6 months get collected by June-July.
Answered
High priority
Plans for fund raise or rights issue to strengthen balance sheet.
Asked by KL, Gojun Capital
Management clearly stated no immediate fund raise and explained existing liquidity sources.
Read the exchange
Question
Are we looking for any fund raise or rights issue to get enough capital to survive?
Viki (CFO)
We have 10% unused bank facilities plus additional 20% government funding. Cash flow from operations was 90 crores despite 8 crore PAT. We are not planning a rights issue.
Evasive
High priority
Guidance for next financial year after repeated misses.
Asked by Wun Sharma, Individual Investor
Management declined to provide any quantitative guidance despite repeated misses.
no specific guidance givenvague optimism
Read the exchange
Question
You have repeatedly missed guidance. What would be your guidance for the next financial year?
Viki (CFO)
We are not giving any specific number on guidance. Difficult phase should be over this year. Next year should be a better number.
Partial answer
Medium priority
How will this year be different with more B2B technical sales?
Asked by Sakit Kapoor, Kapoor and Company
Management described the strategy but gave no quantified impact on financials.
no revenue or profit contribution estimates for new B2B strategy
Read the exchange
Question
How will this year be different in terms of doing more B2B work on technical part and thereby better top line and bottom line?
Surendra (CEO)
We are diversifying from being only feeder for brand business to providing key technicals to other companies. Four new patented molecules are already in production in Q1, accelerating into Q2 and Q3.
Answered
Medium priority
Impact of deferred March sales on Q1 and sales return provisions.
Asked by Sakit Kapoor, Kapoor and Company
Management gave specific percentage reduction in sales returns and directional impact on Q1.
Read the exchange
Question
Sales deferred to Q1 due to price revision expectations. How will that translate? Also, how have sales return provisions worked out?
Viki (CFO)
Q1 will see better top line and bottom line as placements are at higher prices. Sales return as a percentage came down by 10% to ~20-21%. We aim to go below 20% next year.
Answered
High priority
If 50-70 cr sales were not deferred, would losses have been lower?
Asked by Sakit Kapoor, Kapoor and Company
Management quantified the profit impact of deferred sales, explaining the loss magnitude.
Read the exchange
Question
If we had factored that 50 cr sale number, our losses would not have trimmed to a larger extent? How should one explain this 48 cr loss?
Viki (CFO)
That 50-70 crores would have brought around 20-23 crores of profit. So loss would have been less than 15 crores.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Branded EBITDA margin 18-20% | 20% | -17% | Overstated vs filing |
| B2B EBITDA margin ~8% | 8% | -17% | Overstated vs filing |
| Deferred sales would have added 20-23 cr profit | ₹23 cr | ₹-37 cr | Overstated vs filing |
| Loss would have been less than 15 cr without deferral | ₹15 cr | ₹-37 cr | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.